AbbVie's Skyrizi stands to gain as docs move away from older psoriasis meds—Amgen's Otezla included

AbbVie's Skyrizi stands to gain as docs move away from older psoriasis meds—Amgen's Otezla included

Source: 
Fierce Pharma
snippet: 

In an increasingly crowded psoriasis market, a raft of next-gen biologics is looking to topple an older suite of drugs for sales supremacy. Dermatologists seem to be on board with that shift, a good thing for AbbVie's rising star Skyrizi—but for Amgen, which paid a premium for Celgene's Otezla last year, that's bad news.